#United States #New York #Pomerantz LLP #PepGen Inc #FDA Holds

Investors Raise Alarms Over PepGen Inc. Amid Failing Trials

In recent developments within the financial world, Pomerantz Law Firm has announced an investigation into PepGen Inc. (NASDAQ: PEPG), focusing on claims made by investors regarding potential securities fraud and unlawful business practices by the company’s management. This investigation comes at a critical juncture for PepGen following significant setbacks in its clinical trial processes, raising concerns among shareholders and stakeholders alike.

On March 4, 2026, PepGen released a press statement informing the public that the U.S. Food and Drug Administration (FDA) had placed a partial hold on the company's FREEDOM2-DM1 Phase 2 clinical trial. This trial focused on evaluating the efficacy of PGN-EDODM1, a treatment designed for patients suffering from myotonic dystrophy type 1 (DM1). The FDA's concerns were reportedly linked to existing preclinical pharmacology and toxicology studies submitted by PepGen, stirring worries about the safety and viability of its drug candidates.

Securities analysts reacted swiftly to this announcement, leading to a substantial decline in PepGen's stock price. By March 5, 2026, shares had plummeted by $1.25, an alarming drop of around 18.57%, closing at $5.50 per share.

Even more detrimental was the subsequent release on March 30, 2026, where PepGen claimed to share analysis from the 5 mg/kg multiple ascending dose cohort of the same trial. Despite the company emphasizing the clinical data as “promising,” experts noted no substantial improvement in critical patient assessments such as handgrip strength or performance on the 10-meter walk/run test. This revelation significantly impacted investor confidence, causing the stock to tumble by $2.46 per share, a staggering 58.16% decline, with shares closing at $1.77 on March 31, 2026.

Pomerantz Law Firm is advising affected investors to reach out to Danielle Peyton at their office for assistance. With numerous high-profile class-action suits in its history, including successful recoveries on behalf of class members, Pomerantz is well-equipped to handle these claims.

This firm, established by the renowned Abraham L. Pomerantz—often acknowledged as the pioneer of securities class actions—continues its legacy of fighting for shareholder rights and resolving financial grievances efficiently. Having established offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, they have remained a formidable presence in the landscape of corporate and securities litigation.

The outcome of the investigation could hold significant implications for PepGen and its investors. The firm’s previous results do not guarantee similar outcomes, yet it showcases a commitment to ensuring that the recent controversies surrounding PepGen are thoroughly scrutinized and resolved.

As the landscape for biotech firms evolves, these allegations serve as a stark reminder of the precarious nature of clinical trials and the intrinsic link between investor trust and drug efficacy. Stakeholders are encouraged to stay informed as the situation unfolds, with awareness that legal recourse may be a necessary avenue for those misled or financially harmed.

For anyone interested in pursuing actions against PepGen due to the aforementioned events, the Pomerantz Law Firm urges immediate contact. The investigation into PepGen is just the latest chapter in the ongoing discourse on corporate accountability in the biotechnology sector, shedding light on the essential role that law firms play in safeguarding investor rights against potential corporate malfeasance. Stay tuned for further developments as this investigation progresses.